The Economic Burden of Acute Myeloid Leukemia in Iran
| Autor: | Zahra Meshkani, Fateme Mezginejad, Shahin Nargesi, Zeinab Dolatshahi, Vahid Alipour, Reza Jahangiri, Seyed Asadollah Mousavi, Soroush Rad |
|---|---|
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Iranian Journal of Public Health. |
| ISSN: | 2251-6093 2251-6085 3324-3107 |
| Popis: | BackgroundCancer imposes a significant economic burden on the health system and society. Acute myeloid leukemia (AML) is the third deadliest leukemia and is one of the leading health problems worldwide. The present study aims to estimate the economic burden of AML in Iran for 2020.MethodsIn this study, we estimated a prevalence-based on the cost-of-illness of the AML in Iran. A societal perspective was considered, in which the direct costs and productivity losses with the adoption of the human capital approach in the AML cases were estimated for 2020. Moreover, in the present study, several resources including national cancer registry reports, hospital records, occupational data, and interviews with experts were cited.ResultApproximately 98% of patients with AML received induction therapy. The AML economic burden was $ 33243107.39. Indirect costs accounted for 60% of this amount, and direct medical costs made up for 19% of this estimated economic burden.ConclusionThe economic burden of AML in Iran is very significant and due to the increasing prevalence of this disease, it is expected to increase more gradually. Awareness of the costs associated with this disease provides a great opportunity for policymakers and managers of the health systems to improve resource allocation efficiently. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|